ID   FLT3_HUMAN              Reviewed;         993 AA.
AC   P36888; A0AVG9; B7ZLT7; B7ZLT8; F5H0A0; Q13414;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   21-AUG-2007, sequence version 2.
DT   12-OCT-2022, entry version 209.
DE   RecName: Full=Receptor-type tyrosine-protein kinase FLT3;
DE            EC=2.7.10.1;
DE   AltName: Full=FL cytokine receptor;
DE   AltName: Full=Fetal liver kinase-2;
DE            Short=FLK-2;
DE   AltName: Full=Fms-like tyrosine kinase 3;
DE            Short=FLT-3;
DE   AltName: Full=Stem cell tyrosine kinase 1;
DE            Short=STK-1;
DE   AltName: CD_antigen=CD135;
DE   Flags: Precursor;
GN   Name=FLT3; Synonyms=CD135, FLK2, STK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Bone marrow;
RX   PubMed=7507245; DOI=10.1073/pnas.91.2.459;
RA   Small D., Levenstein M., Kim E., Carow C., Amin S., Rockwell P., Witte L.,
RA   Burrow C., Ratajczak M.Z., Gewirtz A.M., Civin C.I.;
RT   "STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+
RT   human bone marrow cells and is involved in the proliferation of early
RT   progenitor/stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:459-463(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT
RP   MET-227.
RC   TISSUE=Lymphocyte;
RX   PubMed=8394751;
RA   Rosnet O., Schiff C., Pebusque M.J., Marchetto S., Tonnelle C., Toiron Y.,
RA   Birg F., Birnbaum D.;
RT   "Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic
RT   cells.";
RL   Blood 82:1110-1119(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT MET-227.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   MET-227.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 783-942 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=2004790; DOI=10.1016/0888-7543(91)90270-o;
RA   Rosnet O., Mattei M.-G., Marchetto S., Birnbaum D.;
RT   "Isolation and chromosomal localization of a novel FMS-like tyrosine kinase
RT   gene.";
RL   Genomics 9:380-385(1991).
RN   [7]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=8637232;
RA   Rosnet O., Buhring H.J., Marchetto S., Rappold I., Lavagna C., Sainty D.,
RA   Arnoulet C., Chabannon C., Kanz L., Hannum C., Birnbaum D.;
RT   "Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of
RT   normal and malignant hematopoietic cells.";
RL   Leukemia 10:238-248(1996).
RN   [8]
RP   INVOLVEMENT IN AML.
RX   PubMed=8946930;
RA   Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y.,
RA   Fujimoto T., Misawa S.;
RT   "Internal tandem duplication of the flt3 gene found in acute myeloid
RT   leukemia.";
RL   Leukemia 10:1911-1918(1996).
RN   [9]
RP   INVOLVEMENT IN AML, SUBUNIT, PHOSPHORYLATION, AND MUTAGENESIS OF TYR-589
RP   AND TYR-591.
RX   PubMed=9737679; DOI=10.1038/sj.leu.2401130;
RA   Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H., Naoe T.;
RT   "Internal tandem duplication of the FLT3 gene is a novel modality of
RT   elongation mutation which causes constitutive activation of the product.";
RL   Leukemia 12:1333-1337(1998).
RN   [10]
RP   FUNCTION IN PROMOTING PHOSPHORYLATION OF SHC1; PTPN6/SHP; PTPN11/SHP-2;
RP   MAPK1/ERK2; MAPK3/ERK1, AUTOPHOSPHORYLATION, AND INTERACTION WITH GRB2.
RX   PubMed=10080542; DOI=10.1002/jlb.65.3.372;
RA   Zhang S., Mantel C., Broxmeyer H.E.;
RT   "Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and
RT   their association with Grb2 and Shc in Baf3/Flt3 cells.";
RL   J. Leukoc. Biol. 65:372-380(1999).
RN   [11]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2; MAPK3/ERK1; STAT5A AND STAT5B,
RP   PHOSPHORYLATION, FUNCTION IN ACTIVATION OF THE RAS PATHWAY, AND INVOLVEMENT
RP   IN AML.
RX   PubMed=11090077;
RA   Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C.,
RA   Gruning W., Kratz-Albers K., Serve S., Steur C., Buchner T., Kienast J.,
RA   Kanakura Y., Berdel W.E., Serve H.;
RT   "Flt3 mutations from patients with acute myeloid leukemia induce
RT   transformation of 32D cells mediated by the Ras and STAT5 pathways.";
RL   Blood 96:3907-3914(2000).
RN   [12]
RP   FUNCTION IN ACTIVATION OF AKT1, AND INVOLVEMENT IN AML.
RX   PubMed=16266983; DOI=10.1158/0008-5472.can-05-0422;
RA   Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J.,
RA   Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E.,
RA   Serve H.;
RT   "Constitutive activation of Akt by Flt3 internal tandem duplications is
RT   necessary for increased survival, proliferation, and myeloid
RT   transformation.";
RL   Cancer Res. 65:9643-9650(2005).
RN   [13]
RP   SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-591,
RP   DEPHOSPHORYLATION BY PTPN1; PTPN6/SHP-1 AND PTPN12, PROTEASOMAL
RP   DEGRADATION, GLYCOSYLATION, AND MUTAGENESIS OF LYS-644.
RX   PubMed=15831474; DOI=10.1128/mcb.25.9.3690-3703.2005;
RA   Schmidt-Arras D.E., Bohmer A., Markova B., Choudhary C., Serve H.,
RA   Bohmer F.D.;
RT   "Tyrosine phosphorylation regulates maturation of receptor tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 25:3690-3703(2005).
RN   [14]
RP   FUNCTION IN ACTIVATION OF STAT5A AND/OR STAT5B, PHOSPHORYLATION AT TYR-591;
RP   TYR-726; TYR-842; TYR-955 AND TYR-969, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND MUTAGENESIS OF TYR-589 AND TYR-591.
RX   PubMed=16627759; DOI=10.1182/blood-2005-11-011429;
RA   Rocnik J.L., Okabe R., Yu J.C., Lee B.H., Giese N., Schenkein D.P.,
RA   Gilliland D.G.;
RT   "Roles of tyrosine 589 and 591 in STAT5 activation and transformation
RT   mediated by FLT3-ITD.";
RL   Blood 108:1339-1345(2006).
RN   [15]
RP   INTERACTION WITH PTPN11/SHP2; LYN; FGR; HCK AND SRC, AUTOPHOSPHORYLATION,
RP   MUTAGENESIS OF TYR-589 AND TYR-599, AND PHOSPHORYLATION AT TYR-572;
RP   SER-574; TYR-589; TYR-591 AND TYR-599.
RX   PubMed=16684964; DOI=10.1182/blood-2005-07-008896;
RA   Heiss E., Masson K., Sundberg C., Pedersen M., Sun J., Bengtsson S.,
RA   Ronnstrand L.;
RT   "Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as
RT   ligand-induced autophosphorylation sites involved in binding of Src family
RT   kinases and the protein tyrosine phosphatase SHP2.";
RL   Blood 108:1542-1550(2006).
RN   [16]
RP   REGION INVOLVED IN REGULATION OF KINASE ACTIVITY, AUTOREGULATORY DOMAIN,
RP   AND INVOLVEMENT IN AML.
RX   PubMed=18305215; DOI=10.1182/blood-2008-01-117770;
RA   Meshinchi S., Stirewalt D.L., Alonzo T.A., Boggon T.J., Gerbing R.B.,
RA   Rocnik J.L., Lange B.J., Gilliland D.G., Radich J.P.;
RT   "Structural and numerical variation of FLT3/ITD in pediatric AML.";
RL   Blood 111:4930-4933(2008).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18490735; DOI=10.4049/jimmunol.180.11.7358;
RA   Kikushige Y., Yoshimoto G., Miyamoto T., Iino T., Mori Y., Iwasaki H.,
RA   Niiro H., Takenaka K., Nagafuji K., Harada M., Ishikawa F., Akashi K.;
RT   "Human Flt3 is expressed at the hematopoietic stem cell and the
RT   granulocyte/macrophage progenitor stages to maintain cell survival.";
RL   J. Immunol. 180:7358-7367(2008).
RN   [18]
RP   PHOSPHORYLATION AT TYR-589; TYR-591; TYR-599; TYR-726; TYR-768; TYR-793;
RP   TYR-842 AND TYR-955.
RX   PubMed=19477218; DOI=10.1016/j.exphem.2009.05.008;
RA   Razumovskaya E., Masson K., Khan R., Bengtsson S., Ronnstrand L.;
RT   "Oncogenic Flt3 receptors display different specificity and kinetics of
RT   autophosphorylation.";
RL   Exp. Hematol. 37:979-989(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-759 AND SER-993, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   FUNCTION IN ACTIVATION OF FES AND FER, AND INTERACTION WITH FES AND FER.
RX   PubMed=20111072; DOI=10.1038/leu.2009.301;
RA   Voisset E., Lopez S., Chaix A., Georges C., Hanssens K., Prebet T.,
RA   Dubreuil P., De Sepulveda P.;
RT   "FES kinases are required for oncogenic FLT3 signaling.";
RL   Leukemia 24:721-728(2010).
RN   [21]
RP   UBIQUITINATION.
RX   PubMed=20508617; DOI=10.1038/leu.2010.114;
RA   Buchwald M., Pietschmann K., Muller J.P., Bohmer F.D., Heinzel T.,
RA   Kramer O.H.;
RT   "Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for
RT   proteasomal degradation.";
RL   Leukemia 24:1412-1421(2010).
RN   [22]
RP   FUNCTION.
RX   PubMed=21067588; DOI=10.1186/1476-4598-9-292;
RA   Chen W., Drakos E., Grammatikakis I., Schlette E.J., Li J., Leventaki V.,
RA   Staikou-Drakopoulou E., Patsouris E., Panayiotidis P., Medeiros L.J.,
RA   Rassidakis G.Z.;
RT   "mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-
RT   mutated acute myeloid leukemia cells.";
RL   Mol. Cancer 9:292-292(2010).
RN   [23]
RP   INTERACTION WITH PTPRJ/DEP1, FUNCTION IN ACTIVATION OF MAPK1/ERK2;
RP   MAPK3/ERK1; PLCG1; STAT5A AND/OR STAT5B, GLYCOSYLATION, UBIQUITINATION, AND
RP   PHOSPHORYLATION AT TYR-572; TYR-589; TYR-591; TYR-599; TYR-768; TYR-793;
RP   TYR-842 AND TYR-955.
RX   PubMed=21262971; DOI=10.1074/jbc.m110.205021;
RA   Arora D., Stopp S., Bohmer S.A., Schons J., Godfrey R., Masson K.,
RA   Razumovskaya E., Ronnstrand L., Tanzer S., Bauer R., Bohmer F.D.,
RA   Muller J.P.;
RT   "Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3
RT   signaling.";
RL   J. Biol. Chem. 286:10918-10929(2011).
RN   [24]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=21516120; DOI=10.1038/onc.2011.110;
RA   Zheng R., Bailey E., Nguyen B., Yang X., Piloto O., Levis M., Small D.;
RT   "Further activation of FLT3 mutants by FLT3 ligand.";
RL   Oncogene 30:4004-4014(2011).
RN   [25]
RP   REVIEW.
RX   PubMed=12951584; DOI=10.1038/nrc1169;
RA   Stirewalt D.L., Radich J.P.;
RT   "The role of FLT3 in haematopoietic malignancies.";
RL   Nat. Rev. Cancer 3:650-665(2003).
RN   [26]
RP   REVIEW.
RX   PubMed=19549778; DOI=10.1158/1078-0432.ccr-08-1123;
RA   Meshinchi S., Appelbaum F.R.;
RT   "Structural and functional alterations of FLT3 in acute myeloid leukemia.";
RL   Clin. Cancer Res. 15:4263-4269(2009).
RN   [27]
RP   INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL7.
RX   PubMed=29691342; DOI=10.1128/mbio.00682-18;
RA   Crawford L.B., Kim J.H., Collins-McMillen D., Lee B.J., Landais I.,
RA   Held C., Nelson J.A., Yurochko A.D., Caposio P.;
RT   "Human Cytomegalovirus Encodes a Novel FLT3 Receptor Ligand Necessary for
RT   Hematopoietic Cell Differentiation and Viral Reactivation.";
RL   MBio 9:0-0(2018).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 564-958, AND ACTIVITY REGULATION.
RX   PubMed=14759363; DOI=10.1016/s1097-2765(03)00505-7;
RA   Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., Lippke J.,
RA   Saxena K.;
RT   "The structural basis for autoinhibition of FLT3 by the juxtamembrane
RT   domain.";
RL   Mol. Cell 13:169-178(2004).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (4.3 ANGSTROMS) OF 27-436 IN COMPLEX WITH FLT3LG,
RP   SUBUNIT, INTERACTION WITH FLT3LG, GLYCOSYLATION AT ASN-43; ASN-100;
RP   ASN-151; ASN-306; ASN-323; ASN-351 AND ASN-354, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND DISULFIDE BONDS.
RX   PubMed=21389326; DOI=10.1182/blood-2011-01-329532;
RA   Verstraete K., Vandriessche G., Januar M., Elegheert J., Shkumatov A.V.,
RA   Desfosses A., Van Craenenbroeck K., Svergun D.I., Gutsche I., Vergauwen B.,
RA   Savvides S.N.;
RT   "Structural insights into the extracellular assembly of the hematopoietic
RT   Flt3 signaling complex.";
RL   Blood 118:60-68(2011).
RN   [30]
RP   VARIANTS TYR-835 DEL; HIS-835 AND TYR-835, AND INVOLVEMENT IN AML.
RX   PubMed=11442493; DOI=10.1046/j.1365-2141.2001.02850.x;
RA   Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R.,
RA   Reilly J.T.;
RT   "Identification of novel FLT-3 Asp835 mutations in adult acute myeloid
RT   leukaemia.";
RL   Br. J. Haematol. 113:983-988(2001).
RN   [31]
RP   VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND TYR-835, CHARACTERIZATION
RP   OF VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND TYR-835,
RP   PHOSPHORYLATION, AND INVOLVEMENT IN AML.
RX   PubMed=11290608; DOI=10.1182/blood.v97.8.2434;
RA   Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S.,
RA   Asou N., Kuriyama K., Yagasaki F., Shimazaki C., Akiyama H., Saito K.,
RA   Nishimura M., Motoji T., Shinagawa K., Takeshita A., Saito H., Ueda R.,
RA   Ohno R., Naoe T.;
RT   "Activating mutation of D835 within the activation loop of FLT3 in human
RT   hematologic malignancies.";
RL   Blood 97:2434-2439(2001).
RN   [32]
RP   VARIANTS GLU-835; HIS-835; TYR-835; ILE-836 DEL AND MET-836, FUNCTION IN
RP   ACTIVATION OF STAT5A AND/OR STAT5B, PHOSPHORYLATION, AND INVOLVEMENT IN
RP   AML.
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric ALL
RT   with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-158; MET-227; ASN-324; VAL-358 AND
RP   ILE-557.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [34]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-194.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S.,
RA   Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A.,
RA   DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor
CC       for the cytokine FLT3LG and regulates differentiation, proliferation
CC       and survival of hematopoietic progenitor cells and of dendritic cells.
CC       Promotes phosphorylation of SHC1 and AKT1, and activation of the
CC       downstream effector MTOR. Promotes activation of RAS signaling and
CC       phosphorylation of downstream kinases, including MAPK1/ERK2 and/or
CC       MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP,
CC       PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type
CC       FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations
CC       that cause constitutive kinase activity promote cell proliferation and
CC       resistance to apoptosis via the activation of multiple signaling
CC       pathways. {ECO:0000269|PubMed:10080542, ECO:0000269|PubMed:11090077,
CC       ECO:0000269|PubMed:14504097, ECO:0000269|PubMed:16266983,
CC       ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:18490735,
CC       ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:21067588,
CC       ECO:0000269|PubMed:21262971, ECO:0000269|PubMed:21516120,
CC       ECO:0000269|PubMed:7507245}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:15831474};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. FLT3LG binding leads to dimerization and activation by
CC       autophosphorylation. {ECO:0000269|PubMed:14759363,
CC       ECO:0000269|PubMed:21516120}.
CC   -!- SUBUNIT: Monomer in the absence of bound FLT3LG. Homodimer in the
CC       presence of bound FLT3LG. Interacts with FIZ1 following ligand
CC       activation (By similarity). Interacts with FES, FER, LYN, FGR, HCK, SRC
CC       and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2. Interacts with
CC       RNF115 and RNF126 (By similarity). {ECO:0000250|UniProtKB:Q00342,
CC       ECO:0000269|PubMed:10080542, ECO:0000269|PubMed:16684964,
CC       ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:21262971,
CC       ECO:0000269|PubMed:21389326, ECO:0000269|PubMed:9737679}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus
CC       protein UL7. {ECO:0000269|PubMed:29691342}.
CC   -!- INTERACTION:
CC       P36888; P00519: ABL1; NbExp=2; IntAct=EBI-3946257, EBI-375543;
CC       P36888; P42684: ABL2; NbExp=3; IntAct=EBI-3946257, EBI-1102694;
CC       P36888; P46108: CRK; NbExp=2; IntAct=EBI-3946257, EBI-886;
CC       P36888; P46109: CRKL; NbExp=2; IntAct=EBI-3946257, EBI-910;
CC       P36888; P06241: FYN; NbExp=2; IntAct=EBI-3946257, EBI-515315;
CC       P36888; Q13322: GRB10; NbExp=6; IntAct=EBI-3946257, EBI-80275;
CC       P36888; Q9Y6K9: IKBKG; NbExp=2; IntAct=EBI-3946257, EBI-81279;
CC       P36888; P06239: LCK; NbExp=2; IntAct=EBI-3946257, EBI-1348;
CC       P36888; P27986: PIK3R1; NbExp=2; IntAct=EBI-3946257, EBI-79464;
CC       P36888; P20936: RASA1; NbExp=2; IntAct=EBI-3946257, EBI-1026476;
CC       P36888; P43405: SYK; NbExp=22; IntAct=EBI-3946257, EBI-78302;
CC       P36888; Q8R4L0: Sla2; Xeno; NbExp=14; IntAct=EBI-3946257, EBI-20766300;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC       Endoplasmic reticulum lumen. Note=Constitutively activated mutant forms
CC       with internal tandem duplications are less efficiently transported to
CC       the cell surface and a significant proportion is retained in an
CC       immature form in the endoplasmic reticulum lumen. The activated kinase
CC       is rapidly targeted for degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P36888-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P36888-2; Sequence=VSP_041796;
CC   -!- TISSUE SPECIFICITY: Detected in bone marrow, in hematopoietic stem
CC       cells, in myeloid progenitor cells and in granulocyte/macrophage
CC       progenitor cells (at protein level). Detected in bone marrow, liver,
CC       thymus, spleen and lymph node, and at low levels in kidney and
CC       pancreas. Highly expressed in T-cell leukemia.
CC       {ECO:0000269|PubMed:18490735, ECO:0000269|PubMed:7507245,
CC       ECO:0000269|PubMed:8394751, ECO:0000269|PubMed:8637232}.
CC   -!- DOMAIN: The juxtamembrane autoregulatory region is important for normal
CC       regulation of the kinase activity and for maintaining the kinase in an
CC       inactive state in the absence of bound ligand. Upon tyrosine
CC       phosphorylation, it mediates interaction with the SH2 domains of
CC       numerous signaling partners. In-frame internal tandem duplications
CC       (ITDs) result in constitutive activation of the kinase. The activity of
CC       the mutant kinase can be stimulated further by FLT3LG binding.
CC   -!- PTM: N-glycosylated, contains complex N-glycans with sialic acid.
CC       {ECO:0000269|PubMed:15831474, ECO:0000269|PubMed:21262971,
CC       ECO:0000269|PubMed:21389326}.
CC   -!- PTM: Autophosphorylated on several tyrosine residues in response to
CC       FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant
CC       kinases that are constitutively activated. Dephosphorylated by
CC       PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12.
CC       Dephosphorylation is important for export from the endoplasmic
CC       reticulum and location at the cell membrane.
CC   -!- PTM: Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein
CC       ligase SIAH1 after autophosphorylation, leading to its proteasomal
CC       degradation. {ECO:0000269|PubMed:20508617,
CC       ECO:0000269|PubMed:21262971}.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of
CC       acute leukemia, a cancer of the white blood cells. AML is a malignant
CC       disease of bone marrow characterized by maturational arrest of
CC       hematopoietic precursors at an early stage of development. Clonal
CC       expansion of myeloid blasts occurs in bone marrow, blood, and other
CC       tissue. Myelogenous leukemias develop from changes in cells that
CC       normally produce neutrophils, basophils, eosinophils and monocytes.
CC       {ECO:0000269|PubMed:11090077, ECO:0000269|PubMed:11290608,
CC       ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097,
CC       ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:18305215,
CC       ECO:0000269|PubMed:8946930, ECO:0000269|PubMed:9737679}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC       Somatic mutations that lead to constitutive activation of FLT3 are
CC       frequent in AML patients. These mutations fall into two classes, the
CC       most common being in-frame internal tandem duplications of variable
CC       length in the juxtamembrane region that disrupt the normal regulation
CC       of the kinase activity. Likewise, point mutations in the activation
CC       loop of the kinase domain can result in a constitutively activated
CC       kinase.
CC   -!- MISCELLANEOUS: Can be used as diagnostic tool to establish the exact
CC       cause of acute myeloid leukemia, and to determine the optimal therapy.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FLT3ID144.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U02687; AAA18947.1; -; mRNA.
DR   EMBL; Z26652; CAA81393.1; -; mRNA.
DR   EMBL; AL356915; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445262; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591024; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08424.1; -; Genomic_DNA.
DR   EMBL; BC126350; AAI26351.1; -; mRNA.
DR   EMBL; BC144039; AAI44040.1; -; mRNA.
DR   EMBL; BC144040; AAI44041.1; -; mRNA.
DR   EMBL; L36162; AAA35487.1; -; mRNA.
DR   CCDS; CCDS31953.1; -. [P36888-1]
DR   PIR; A36873; A36873.
DR   PIR; A39061; A39061.
DR   RefSeq; NP_004110.2; NM_004119.2. [P36888-1]
DR   PDB; 1RJB; X-ray; 2.10 A; A=564-958.
DR   PDB; 3QS7; X-ray; 4.30 A; E/F/G/H=27-436.
DR   PDB; 3QS9; X-ray; 7.80 A; E/F/G/H=27-540.
DR   PDB; 4RT7; X-ray; 3.10 A; A=564-958.
DR   PDB; 4XUF; X-ray; 3.20 A; A/B=600-947.
DR   PDB; 5X02; X-ray; 2.40 A; A=564-958.
DR   PDB; 6IL3; X-ray; 2.50 A; A=564-958.
DR   PDB; 6JQR; X-ray; 2.20 A; A=571-951.
DR   PDBsum; 1RJB; -.
DR   PDBsum; 3QS7; -.
DR   PDBsum; 3QS9; -.
DR   PDBsum; 4RT7; -.
DR   PDBsum; 4XUF; -.
DR   PDBsum; 5X02; -.
DR   PDBsum; 6IL3; -.
DR   PDBsum; 6JQR; -.
DR   AlphaFoldDB; P36888; -.
DR   SMR; P36888; -.
DR   BioGRID; 108610; 141.
DR   DIP; DIP-59769N; -.
DR   IntAct; P36888; 222.
DR   MINT; P36888; -.
DR   STRING; 9606.ENSP00000241453; -.
DR   BindingDB; P36888; -.
DR   ChEMBL; CHEMBL1974; -.
DR   DrugBank; DB12742; Amuvatinib.
DR   DrugBank; DB12267; Brigatinib.
DR   DrugBank; DB12500; Fedratinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugBank; DB06469; Lestaurtinib.
DR   DrugBank; DB06080; Linifanib.
DR   DrugBank; DB06595; Midostaurin.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB12978; Pexidartinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB15822; Pralsetinib.
DR   DrugBank; DB12874; Quizartinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05465; Tandutinib.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugBank; DB05014; XL999.
DR   DrugCentral; P36888; -.
DR   GuidetoPHARMACOLOGY; 1807; -.
DR   GlyGen; P36888; 10 sites.
DR   iPTMnet; P36888; -.
DR   PhosphoSitePlus; P36888; -.
DR   BioMuta; FLT3; -.
DR   DMDM; 156630887; -.
DR   CPTAC; CPTAC-2792; -.
DR   jPOST; P36888; -.
DR   MassIVE; P36888; -.
DR   MaxQB; P36888; -.
DR   PaxDb; P36888; -.
DR   PeptideAtlas; P36888; -.
DR   PRIDE; P36888; -.
DR   ProteomicsDB; 55226; -. [P36888-1]
DR   ProteomicsDB; 55227; -. [P36888-2]
DR   ABCD; P36888; 40 sequenced antibodies.
DR   Antibodypedia; 4334; 1605 antibodies from 50 providers.
DR   DNASU; 2322; -.
DR   Ensembl; ENST00000241453.12; ENSP00000241453.7; ENSG00000122025.15. [P36888-1]
DR   GeneID; 2322; -.
DR   KEGG; hsa:2322; -.
DR   MANE-Select; ENST00000241453.12; ENSP00000241453.7; NM_004119.3; NP_004110.2.
DR   UCSC; uc001urw.3; human. [P36888-1]
DR   CTD; 2322; -.
DR   DisGeNET; 2322; -.
DR   GeneCards; FLT3; -.
DR   HGNC; HGNC:3765; FLT3.
DR   HPA; ENSG00000122025; Tissue enhanced (bone marrow, brain, lymphoid tissue).
DR   MalaCards; FLT3; -.
DR   MIM; 136351; gene.
DR   MIM; 601626; phenotype.
DR   neXtProt; NX_P36888; -.
DR   OpenTargets; ENSG00000122025; -.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 98833; Acute myeloblastic leukemia without maturation.
DR   Orphanet; 98829; Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22).
DR   Orphanet; 98832; Acute myeloid leukemia with minimal differentiation.
DR   Orphanet; 102724; Acute myeloid leukemia with t(8;21)(q22;q22) translocation.
DR   Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2).
DR   Orphanet; 589534; Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2).
DR   Orphanet; 589595; Mixed phenotype acute leukemia with t(v;11q23.3).
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA28181; -.
DR   VEuPathDB; HostDB:ENSG00000122025; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000160575; -.
DR   HOGENOM; CLU_000288_49_1_1; -.
DR   InParanoid; P36888; -.
DR   OMA; EVQIHQD; -.
DR   OrthoDB; 719800at2759; -.
DR   PhylomeDB; P36888; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P36888; -.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-9607240; FLT3 Signaling.
DR   Reactome; R-HSA-9645135; STAT5 Activation.
DR   Reactome; R-HSA-9702509; FLT3 mutants bind TKIs.
DR   Reactome; R-HSA-9702518; STAT5 activation downstream of FLT3 ITD mutants.
DR   Reactome; R-HSA-9702569; KW2449-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702577; semaxanib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702581; crenolanib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702590; gilteritinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702596; lestaurtinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702600; midostaurin-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702605; pexidartinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702614; ponatinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702620; quizartinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702624; sorafenib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702632; sunitinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702636; tandutinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9702998; linifanib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9703009; tamatinib-resistant FLT3 mutants.
DR   Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants.
DR   Reactome; R-HSA-9706369; Negative regulation of FLT3.
DR   Reactome; R-HSA-9706374; FLT3 signaling through SRC family kinases.
DR   Reactome; R-HSA-9706377; FLT3 signaling by CBL mutants.
DR   SignaLink; P36888; -.
DR   SIGNOR; P36888; -.
DR   BioGRID-ORCS; 2322; 21 hits in 1107 CRISPR screens.
DR   ChiTaRS; FLT3; human.
DR   EvolutionaryTrace; P36888; -.
DR   GeneWiki; CD135; -.
DR   GenomeRNAi; 2322; -.
DR   Pharos; P36888; Tclin.
DR   PRO; PR:P36888; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P36888; protein.
DR   Bgee; ENSG00000122025; Expressed in cerebellar hemisphere and 103 other tissues.
DR   ExpressionAtlas; P36888; baseline and differential.
DR   Genevisible; P36888; HS.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004896; F:cytokine receptor activity; ISS:UniProtKB.
DR   GO; GO:0019838; F:growth factor binding; IBA:GO_Central.
DR   GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IEA:Ensembl.
DR   GO; GO:0043621; F:protein self-association; IMP:CAFA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor activity; TAS:ProtInc.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; ISS:UniProtKB.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0035726; P:common myeloid progenitor cell proliferation; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IDA:MGI.
DR   GO; GO:0001776; P:leukocyte homeostasis; ISS:UniProtKB.
DR   GO; GO:0046651; P:lymphocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; TAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; TAS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; TAS:UniProtKB.
DR   GO; GO:0002328; P:pro-B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR030118; FLT3.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF356; PTHR24416:SF356; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Disease variant;
KW   Disulfide bond; Endoplasmic reticulum; Glycoprotein;
KW   Host-virus interaction; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Receptor;
KW   Reference proteome; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   CHAIN           27..993
FT                   /note="Receptor-type tyrosine-protein kinase FLT3"
FT                   /id="PRO_0000016778"
FT   TOPO_DOM        27..543
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        544..563
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        564..993
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          253..343
FT                   /note="Ig-like C2-type"
FT   DOMAIN          610..943
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          591..597
FT                   /note="Important for normal regulation of the kinase
FT                   activity and for maintaining the kinase in an inactive
FT                   state in the absence of bound ligand"
FT   ACT_SITE        811
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         616..624
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         644
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         572
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:16684964,
FT                   ECO:0000269|PubMed:21262971"
FT   MOD_RES         574
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16684964"
FT   MOD_RES         589
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16684964,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         591
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15831474,
FT                   ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:16684964,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         599
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16684964,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         726
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:19477218"
FT   MOD_RES         759
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         768
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19477218,
FT                   ECO:0000269|PubMed:21262971"
FT   MOD_RES         793
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19477218,
FT                   ECO:0000269|PubMed:21262971"
FT   MOD_RES         842
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         955
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:19477218, ECO:0000269|PubMed:21262971"
FT   MOD_RES         969
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:16627759"
FT   MOD_RES         993
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   CARBOHYD        43
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        100
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        151
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        306
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        323
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        351
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        354
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:21389326"
FT   CARBOHYD        473
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   CARBOHYD        502
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   CARBOHYD        541
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        35..65
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        103..114
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        199..206
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        232..241
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        272..330
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        368..407
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   DISULFID        381..392
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:21389326"
FT   VAR_SEQ         807..847
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041796"
FT   VARIANT         7
FT                   /note="D -> G (in dbSNP:rs12872889)"
FT                   /id="VAR_034677"
FT   VARIANT         158
FT                   /note="V -> A (in dbSNP:rs56321896)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042069"
FT   VARIANT         194
FT                   /note="V -> M (in dbSNP:rs146030737)"
FT                   /evidence="ECO:0000269|PubMed:18987736"
FT                   /id="VAR_054149"
FT   VARIANT         227
FT                   /note="T -> M (in dbSNP:rs1933437)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8394751,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_034678"
FT   VARIANT         324
FT                   /note="D -> N (in dbSNP:rs35602083)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042070"
FT   VARIANT         358
FT                   /note="D -> V (in dbSNP:rs34172843)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042071"
FT   VARIANT         417
FT                   /note="I -> L (in dbSNP:rs56090538)"
FT                   /id="VAR_061291"
FT   VARIANT         557
FT                   /note="V -> I (in dbSNP:rs35958982)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042072"
FT   VARIANT         835
FT                   /note="D -> E (in acute lymphoblastic leukemia patients and
FT                   acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121913487)"
FT                   /evidence="ECO:0000269|PubMed:11290608,
FT                   ECO:0000269|PubMed:14504097"
FT                   /id="VAR_065679"
FT   VARIANT         835
FT                   /note="D -> H (in acute lymphoblastic leukemia patients and
FT                   in acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121913488)"
FT                   /evidence="ECO:0000269|PubMed:11290608,
FT                   ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"
FT                   /id="VAR_065680"
FT   VARIANT         835
FT                   /note="D -> N (in acute lymphoblastic leukemia patients and
FT                   in acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121913488)"
FT                   /evidence="ECO:0000269|PubMed:11290608"
FT                   /id="VAR_065681"
FT   VARIANT         835
FT                   /note="D -> V (in acute lymphoblastic leukemia patients and
FT                   in acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121909646)"
FT                   /evidence="ECO:0000269|PubMed:11290608"
FT                   /id="VAR_065682"
FT   VARIANT         835
FT                   /note="D -> Y (in acute lymphoblastic leukemia patients and
FT                   in acute myelogenous leukemia patients; somatic mutation;
FT                   constitutively activated; dbSNP:rs121913488)"
FT                   /evidence="ECO:0000269|PubMed:11290608,
FT                   ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097"
FT                   /id="VAR_065683"
FT   VARIANT         836
FT                   /note="I -> M (in acute lymphoblastic leukemia patients;
FT                   somatic mutation; dbSNP:rs121913232)"
FT                   /evidence="ECO:0000269|PubMed:14504097"
FT                   /id="VAR_065684"
FT   MUTAGEN         589
FT                   /note="Y->F: Reduced phosphorylation of the wild-type
FT                   kinase in response to ligand binding. No effect on the
FT                   phosphorylation of the constitutively activated mutant
FT                   kinase variants. Abolishes activation of STAT5A."
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:16684964, ECO:0000269|PubMed:9737679"
FT   MUTAGEN         591
FT                   /note="Y->F: No significant effect on tyrosine
FT                   phosphorylation. Abolishes activation of STAT5A."
FT                   /evidence="ECO:0000269|PubMed:16627759,
FT                   ECO:0000269|PubMed:9737679"
FT   MUTAGEN         599
FT                   /note="Y->F: Abolishes interaction with PTPN11/SHP2 and
FT                   phosphorylation of PTPN11/SHP2."
FT                   /evidence="ECO:0000269|PubMed:16684964"
FT   MUTAGEN         644
FT                   /note="K->A: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15831474"
FT   CONFLICT        8
FT                   /note="G -> A (in Ref. 1; AAA18947)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        10..11
FT                   /note="QL -> TV (in Ref. 1; AAA18947)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        71
FT                   /note="S -> N (in Ref. 5; AAI44040)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        78
FT                   /note="A -> R (in Ref. 2; CAA81393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        346
FT                   /note="E -> G (in Ref. 1; AAA18947)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        940
FT                   /note="T -> H (in Ref. 6; AAA35487)"
FT                   /evidence="ECO:0000305"
FT   STRAND          575..581
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          583..585
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          589..591
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           594..596
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           601..603
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           607..609
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          610..618
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          620..631
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          633..636
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          638..646
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           656..668
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          677..681
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          683..686
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          688..692
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           699..704
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   TURN            705..708
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           785..804
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          807..809
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           814..816
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          817..820
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   TURN            821..823
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          824..827
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           831..833
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           836..838
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          842..845
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   STRAND          848..850
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           852..854
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           857..862
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           867..881
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   TURN            882..884
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           896..903
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           916..925
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           930..932
FT                   /evidence="ECO:0007829|PDB:1RJB"
FT   HELIX           936..946
FT                   /evidence="ECO:0007829|PDB:1RJB"
SQ   SEQUENCE   993 AA;  112903 MW;  6C1995718F352ECE CRC64;
     MPALARDGGQ LPLLVVFSAM IFGTITNQDL PVIKCVLINH KNNDSSVGKS SSYPMVSESP
     EDLGCALRPQ SSGTVYEAAA VEVDVSASIT LQVLVDAPGN ISCLWVFKHS SLNCQPHFDL
     QNRGVVSMVI LKMTETQAGE YLLFIQSEAT NYTILFTVSI RNTLLYTLRR PYFRKMENQD
     ALVCISESVP EPIVEWVLCD SQGESCKEES PAVVKKEEKV LHELFGTDIR CCARNELGRE
     CTRLFTIDLN QTPQTTLPQL FLKVGEPLWI RCKAVHVNHG FGLTWELENK ALEEGNYFEM
     STYSTNRTMI RILFAFVSSV ARNDTGYYTC SSSKHPSQSA LVTIVEKGFI NATNSSEDYE
     IDQYEEFCFS VRFKAYPQIR CTWTFSRKSF PCEQKGLDNG YSISKFCNHK HQPGEYIFHA
     ENDDAQFTKM FTLNIRRKPQ VLAEASASQA SCFSDGYPLP SWTWKKCSDK SPNCTEEITE
     GVWNRKANRK VFGQWVSSST LNMSEAIKGF LVKCCAYNSL GTSCETILLN SPGPFPFIQD
     NISFYATIGV CLLFIVVLTL LICHKYKKQF RYESQLQMVQ VTGSSDNEYF YVDFREYEYD
     LKWEFPRENL EFGKVLGSGA FGKVMNATAY GISKTGVSIQ VAVKMLKEKA DSSEREALMS
     ELKMMTQLGS HENIVNLLGA CTLSGPIYLI FEYCCYGDLL NYLRSKREKF HRTWTEIFKE
     HNFSFYPTFQ SHPNSSMPGS REVQIHPDSD QISGLHGNSF HSEDEIEYEN QKRLEEEEDL
     NVLTFEDLLC FAYQVAKGME FLEFKSCVHR DLAARNVLVT HGKVVKICDF GLARDIMSDS
     NYVVRGNARL PVKWMAPESL FEGIYTIKSD VWSYGILLWE IFSLGVNPYP GIPVDANFYK
     LIQNGFKMDQ PFYATEEIYI IMQSCWAFDS RKRPSFPNLT SFLGCQLADA EEAMYQNVDG
     RVSECPHTYQ NRRPFSREMD LGLLSPQAQV EDS
//
